Clinical Trial Update: Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas

View source ↗

Summary

This clinical trial update examines the prognostic value of the P63 marker in adenocarcinomas of the lung, breast, and pancreas, with the current status listed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Lung Adenocarcinoma
• Pancreatic Ductal Adenocarcinoma

Snippet

Sponsor: Rambam Health Care Campus | Conditions: Lung Adenocarcinoma, Breast Adenocarcinoma | Status: UNKNOWN